Glycemic control with GlucoTab using insulin degludec in non-critically ill patients with type 2 diabetes at the general ward

Abstract

Introduction: Glycemic control is tightly linked to clinical outcomes in patients with diabetes. Using a clinical decision support system (GlucoTab®) improved glycemic control in previous studies, therefore we studied the effects of using GlucoTab® with a novel basal insulin analogue. (1–3) Objective: The aim of this clinical trial was to investigate and analyze the clinical efficacy, safety, and usability of GlucoTab® for glycemic control, specifically in combination with the ultralong-acting basal insulin degludec and the rapid-acting insulin aspart in hospitalized patients with diabetes mellitus type 2. Methods: GlucoTab® was used for diabetes management on 30 non-critically ill hospitalized patients at the Division of Endocrinology and Diabetology at the Department of Internal Medicine in Graz to investigate the efficacy of the system when used with insulin degludec. GlucoTab® uses an algorithm to support the management of patients with diabetes using insulin degludec (Tresiba®, an ultralong-acting basal insulin analogue) and insulin aspart (NovoRapid®, a rapid-acting insulin analogue). Blood glucose checks were performed pre-meal and at bedtime, as well as blinded continuous subcutaneous glucose monitoring (using the Abbott FreeStyle Libre Pro Flash Glucose Monitoring System) to better understand glycemic excursions over time. Results: The blood glucose target range of 70 – 140 mg/dl was achieved with 52.2 ± 10.2% (n=377) of blood glucose measurements falling into that range from a total of 722 measurements. The rate of hypoglycemia was low, with only 1.25% of blood glucose measurements at

Date of Award	2021
Original language	English
Awarding Institution	Medical University Graz
Supervisor	Julia Mader (Supervisor) & Felix Aberer (Co-supervisor)